Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Fortrea Holdings's Enterprise Value for the quarter that ended in Jun. 2026 was $2,604 Mil.
Fortrea Holdings's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fortrea Holdings EV-to-EBIT Related Terms
Fortrea Holdings EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Fortrea Holdings's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Fortrea Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fortrea Holdings EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fortrea Holdings's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Fortrea Holdings's EV-to-EBIT falls into.
Fortrea Holdings's current Enterprise Value is $2,743 Mil.
Fortrea Holdings's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fortrea Holdings (FTRE) has a EV-to-EBIT of 428.59 as of Jul. 31, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Fortrea Holdings and its competitors. According to the industry distribution chart, Fortrea Holdings ranks #377 out of 382 companies in the Biotechnology industry, placing it in the top 98.7%.
Is Fortrea Holdings' EV-to-EBIT too high?
Fortrea Holdings' current EV-to-EBIT is 428.59. The Biotechnology industry median EV-to-EBIT is 12.56. Fortrea Holdings' value of 428.59 is 3313.7% above this industry median. Based on the distribution chart, Fortrea Holdings ranks #377 out of 382 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Fortrea Holdings has a GF Score™ of 65/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fortrea Holdings' EV-to-EBIT compare to SNDX and KARD?
According to the Biotechnology industry distribution chart, Fortrea Holdings ranks #377 out of 382 companies for EV-to-EBIT. This places Fortrea Holdings in the lower half of its industry. The industry median EV-to-EBIT is 12.56. Fortrea Holdings' value of 428.59 is 3313.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 12.56, based on 382 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fortrea Holdings's current EV-to-EBIT of 428.59 is 3313.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Fortrea Holdings and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 12.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fortrea Holdings's current EV-to-EBIT is 428.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fortrea Holdings stock overvalued right now?
Based on GuruFocus' analysis, Fortrea Holdings (FTRE) is currently considered Modestly Overvalued. The stock's GF Value™ is $16.99, compared to a current price of $18.87 — trading 11% above its estimated fair value. The current EV-to-EBIT is 428.59 and 3313.7% above the Biotechnology industry median of 12.56. Fortrea Holdings' overall GF Score™ is 65/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Fortrea Holdings (FTRE), the current EV-to-EBIT is 428.59 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fortrea Holdings (FTRE) Overvalued in 2026?
Based on GuruFocus' analysis, Fortrea Holdings stock appears to be overvalued.
The current stock price of $18.87 is trading 11% above its estimated GF Value™ of $16.99.
GuruFocus considers Fortrea Holdings to be Modestly Overvalued.
Key valuation signals for FTRE:
EV-to-EBIT: 428.59
GF Value™: $16.99 vs. price of $18.87 (11% above fair value)
Industry Position: 3313.7% above the Biotechnology median (#377 of 382)
No single metric tells the full story. See the FTRE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.
65GF Score
Get the complete analysis for FTRE
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FTRE has been successfully added to your 
